Morgan Caryl N, Rowe Renarta
Janet Shaw Clinic,Brooklands,Marston Green,Birmingham,B37 7HL,England.
West Midlands Forensic Rotation,England.
Ir J Psychol Med. 2003 Sep;20(3):102-104. doi: 10.1017/S0790966700007801.
No information has been published on the incidence of neuroleptic malignant syndrome in learning disability. However, some studies of individuals who have developed neuroleptic malignant syndrome have suggested that individuals with learning disabilities may be over represented. This study aims to identify the association between learning disability and neuroleptic malignant syndrome.
A retrospective case-note analysis was performed with psychiatric case notes for clients with learning disability, in two geographical catchment areas. It was recorded whether clients had been exposed to neuroleptics, and whether any neurological symptoms had subsequently developed which could have been suggestive of neuroleptic malignant syndrome.
It was found that 301 individuals had been exposed to neuroleptics, out of 570 case notes examined. Only one case of neuroleptic malignant syndrome was identified, giving a lifetime prevalence rate of 0.3%.
This study failed to demonstrate a higher than expected prevalence of neuroleptic malignant syndrome in clients with learning disability exposed to neuroleptics.
关于学习障碍者中抗精神病药恶性综合征的发病率尚无公开信息。然而，一些针对已发生抗精神病药恶性综合征个体的研究表明，学习障碍者在其中的占比可能过高。本研究旨在确定学习障碍与抗精神病药恶性综合征之间的关联。
对两个地理区域内有学习障碍的客户的精神科病例记录进行回顾性病例分析。记录客户是否接触过抗精神病药，以及随后是否出现任何可能提示抗精神病药恶性综合征的神经症状。
在检查的570份病例记录中，发现301人接触过抗精神病药。仅确诊1例抗精神病药恶性综合征，终生患病率为0.3%。
本研究未能证明接触抗精神病药的学习障碍患者中抗精神病药恶性综合征的患病率高于预期。
